A third anti-SARS-CoV-2 mRNA dose does not overcome the pejorative impact of anti-CD20 therapy and/or low immunoglobulin levels in patients with lymphoma or chronic lymphocytic leukemia.

Authors :: Kohn M
Delord M
Chbat M
Guemriche A
Merabet F
Roupie AL
Lombion N
Farhat H
Longval T
Cabannes-Hamy A
Lambert J
Marque-Juillet S
Raggueneau V
Osman J
Spentchian M
Rigaudeau S
Rousselot P
Besson C
Source :: Haematologica [Haematologica] 2022 Jun 01; Vol. 107 (6), pp. 1454-1459. Date of Electronic Publication: 2022 Jun 01.
Publication Year :: 2022

Subjects :: Antigens, CD20 genetics
Humans
Immunoglobulins
RNA, Messenger
Rituximab therapeutic use
COVID-19
Leukemia, Lymphocytic, Chronic, B-Cell drug therapy
Leukemia, Lymphocytic, Chronic, B-Cell genetics
Leukemia, Lymphocytic, Chronic, B-Cell pathology
Lymphoma drug therapy

Full Text Access

Tools